# Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

> **NCT01178697** · PHASE2 · UNKNOWN · sponsor: **Shahid Beheshti University of Medical Sciences**

## Conditions studied

- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** Bevasizumab
- **DRUG:** Triamcinolone Acetonide

## Key facts

- **NCT ID:** NCT01178697
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-12
- **Target enrollment:** — (—)
- **Last updated:** 2010-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178697, "Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01178697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*